The relationship between cholesterol and testosterone is one of the more misunderstood corners of hormone health. Testosterone is a steroid hormone synthesized from cholesterol, and once it circulates in the body, it in turn interacts with the enzymes and receptors that regulate HDL and LDL levels. For anyone considering or currently undergoing testosterone replacement therapy (TRT), understanding this two-way relationship matters, because lipid changes are among the more consistently reported laboratory shifts associated with treatment.
This article explains how testosterone and cholesterol are metabolically connected, what peer-reviewed research – including randomized trials and meta-analyses – actually shows about lipid changes during testosterone therapy, and what practical monitoring and lifestyle approaches may help support healthy cholesterol levels during treatment. It also covers safety considerations and when a conversation with a healthcare provider is appropriate. None of this is intended as personal medical advice; it is meant to help you ask better questions of your own care team.
Background: How Testosterone Influences Cholesterol and Lipid Metabolism
Cholesterol is the biochemical starting material for all steroid hormones, including testosterone, estrogen, and cortisol. The body converts cholesterol into pregnenolone and then, through a series of enzymatic steps, into testosterone in the testes (and, in smaller amounts, the adrenal glands and ovaries). This is the first half of the cholesterol and testosterone relationship: cholesterol is literally the raw material testosterone is built from.
The second half runs in the opposite direction – testosterone itself appears to influence how the liver processes lipoproteins. Research suggests testosterone may increase the activity of hepatic lipase, an enzyme that breaks down HDL particles, which is one proposed mechanism behind the HDL reductions seen with some forms of testosterone therapy (Whitsel et al., Am J Med, 200100833-6)). Testosterone may also affect LDL receptor activity and triglyceride clearance, though the direction and magnitude of these effects appear to depend on baseline metabolic health, dose, and how the hormone is administered.
This bidirectional relationship helps explain why testosterone and cholesterol show up together so often in both endocrinology and cardiology literature. It also underscores why lipid panels are a standard part of monitoring for anyone on hormone optimization protocols – not as an afterthought, but as a core piece of the metabolic picture.
What Research Shows About Testosterone Therapy and Cholesterol
The evidence on testosterone therapy and cholesterol is more nuanced than a single headline suggests, and it has evolved over more than two decades of study.
An early, frequently cited meta-analysis pooling 19 studies of intramuscular testosterone esters in hypogonadal men found that testosterone therapy was associated with reductions in total cholesterol and LDL cholesterol, but also with a decrease in HDL cholesterol, particularly at higher, non-physiologic doses (Whitsel et al., Am J Med, 200100833-6)). This finding – lower LDL alongside lower HDL – is part of why testosterone and cholesterol research has historically produced mixed headlines: some changes look favorable, others look less so, depending on which lipid marker is emphasized.
A later meta-analysis of randomized controlled trials in middle-aged and older men found that testosterone administration was associated with modest reductions in total cholesterol, with more variable effects on LDL and HDL depending on baseline hormone status and trial design (Isidori et al., Clin Endocrinol, 2005). More recent research has focused specifically on men with type 2 diabetes and metabolic syndrome, populations where lipid abnormalities are already common. A meta-analysis of seven randomized controlled trials in hypogonadal men with type 2 diabetes found that testosterone supplementation significantly decreased total cholesterol and triglycerides, with HDL improvements observed in some but not all study populations (Zhang et al., Andrology, 2018). A broader 2024 systematic review of testosterone replacement therapy in metabolic syndrome similarly reported favorable trends in triglycerides and waist circumference, with less consistent effects on LDL and HDL across trials (Mlynarz et al., Int J Mol Sci, 2024).
Perhaps the most consequential recent evidence comes not from lipid panels directly but from cardiovascular outcomes. The TRAVERSE trial, a large randomized, placebo-controlled trial involving more than 5,000 middle-aged and older men with hypogonadism and existing or elevated cardiovascular risk, found that testosterone-replacement therapy was noninferior to placebo for the incidence of major adverse cardiac events over a median follow-up of nearly two years (Lincoff et al., N Engl J Med, 2023). This is reassuring at the level of hard cardiovascular events, though the same trial also reported a higher incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group – a reminder that lipid changes are only one piece of the broader cardiovascular safety picture.
Taken together, this body of research indicates that testosterone and cholesterol changes during TRT tend to be real but modest, vary by formulation and dose, and do not appear – in the largest and most rigorous trial to date – to translate into a clear increase in major cardiac events. That said, individual responses vary, which is why ongoing lipid monitoring remains part of responsible TRT management rather than a one-time checkbox.
Managing and Monitoring Cholesterol During TRT
Because testosterone therapy can shift lipid markers in either direction depending on the individual, monitoring is a practical necessity rather than an optional extra. A baseline comprehensive lipid panel before starting treatment, followed by periodic rechecks (commonly around three and twelve months, then annually, though your prescribing physician determines the schedule), allows any meaningful shifts to be caught early.
For readers asking how to lower cholesterol on TRT specifically, the honest answer is that the same evidence-based strategies used outside of hormone therapy apply, layered on top of routine lab monitoring rather than replacing it:
- Dietary pattern. Diets emphasizing fiber, unsaturated fats, and lower intake of refined carbohydrates and saturated fat are consistently associated with more favorable LDL and triglyceride levels in the general population, and there is no biological reason to expect this relationship to differ for someone on testosterone therapy.
- Aerobic and resistance exercise. Regular physical activity is associated with higher HDL and lower triglycerides in multiple population studies, and exercise may complement the lean-mass-supporting effects of testosterone itself.
- Weight and waist circumference management. Because visceral fat is closely tied to unfavorable lipid patterns, tracking body composition alongside hormone levels can provide a fuller picture than testosterone or cholesterol numbers viewed in isolation.
- Avoiding non-physiologic dosing. Some of the more pronounced HDL reductions seen in older lipid research were associated with supraphysiologic testosterone doses rather than doses that restore levels to a normal physiological range, reinforcing the value of individualized, monitored dosing.
- Reviewing other cardiovascular risk factors. Blood pressure, fasting glucose, inflammatory markers, and family history all factor into an accurate risk picture and should be reviewed alongside lipid results, not instead of them.
None of these steps are a substitute for medical supervision, but together they represent the evidence-informed toolkit most relevant to someone managing cholesterol and testosterone together during treatment.
Safety and Practical Considerations
Cardiovascular risk monitoring should be a routine part of any testosterone therapy program, not an exception reserved for people with existing heart disease. Because the TRAVERSE trial specifically enrolled men with elevated cardiovascular risk and still found testosterone therapy noninferior to placebo for major cardiac events, current evidence does not support withholding testosterone therapy from appropriate candidates purely on cholesterol grounds – but it also does not eliminate the need for individualized risk assessment (Lincoff et al., N Engl J Med, 2023).
Signs that warrant a prompt conversation with a healthcare provider include a lipid panel showing a significant rise in LDL or a significant fall in HDL after starting treatment, new or worsening chest discomfort, unexplained shortness of breath, leg swelling or pain (which could signal a blood clot), or an irregular heartbeat. Because testosterone therapy is typically prescribed and monitored by a physician, these changes should be reported to that provider rather than managed independently.
It’s also worth noting that hematocrit, blood pressure, and prostate-specific markers are typically monitored alongside lipids during TRT, since testosterone can affect red blood cell production and other systems relevant to cardiovascular risk. A comprehensive view of these markers, rather than cholesterol in isolation, gives the clearest sense of how an individual is responding to treatment.
Frequently Asked Questions
Does testosterone therapy raise or lower cholesterol?
Research shows mixed effects depending on the lipid marker, dose, and formulation. Several meta-analyses report reductions in total cholesterol and LDL with testosterone therapy, while HDL may decrease, particularly at higher doses, though results vary across studies and populations.
How to lower cholesterol on TRT if my levels rise after starting treatment?
The same evidence-based approaches used generally – improving diet quality, increasing aerobic and resistance exercise, managing weight, and ensuring testosterone dosing stays within a physiological range – are the primary tools, alongside regular lipid monitoring with your prescribing physician, who may adjust dose or formulation if needed.
Is the relationship between testosterone and cholesterol dangerous?
Not inherently. The TRAVERSE trial, the largest cardiovascular safety trial of testosterone therapy to date, found that testosterone-replacement therapy was noninferior to placebo for major adverse cardiac events, even in men with elevated baseline cardiovascular risk. Lipid changes should still be monitored, but they have not been shown to translate into a clear increase in major cardiac events in this trial.
How often should cholesterol be checked while on testosterone therapy?
Most protocols include a baseline lipid panel before starting therapy and periodic rechecks, often around three and twelve months and then annually, though the exact schedule should be set by the prescribing physician based on individual risk factors and response.
Can diet and exercise offset any negative cholesterol changes from TRT?
Diet and exercise are strongly associated with favorable lipid patterns in general population research, and there’s no reason to expect this relationship would not apply during testosterone therapy. They are best viewed as complementary to, not a replacement for, medical monitoring.
Does low testosterone itself affect cholesterol?
Yes. Low testosterone has been associated with less favorable lipid and metabolic profiles in observational research, which is part of why the testosterone and cholesterol relationship is studied from both directions – the effect of low testosterone on lipids, and the effect of testosterone therapy on lipids.
Are all forms of testosterone therapy equally likely to affect cholesterol?
Not necessarily. Older research suggests that higher, non-physiologic doses of injectable testosterone esters were associated with more pronounced HDL reductions than doses that restore levels to a normal physiological range, which is one reason individualized dosing and monitoring matter.
Should I stop TRT if my cholesterol changes?
That decision should always be made with your prescribing physician, who can evaluate the full clinical picture, including the degree of change, your overall cardiovascular risk profile, and other lab markers, rather than reacting to a single lipid value in isolation.
Key Takeaways
- Cholesterol and testosterone have a bidirectional relationship: cholesterol is the biochemical precursor to testosterone, while testosterone in turn influences how the liver processes HDL and LDL.
- Meta-analyses of testosterone therapy show reductions in total cholesterol and LDL in many studies, with more variable effects on HDL depending on dose and formulation.
- The TRAVERSE trial, the largest cardiovascular safety study of testosterone therapy to date, found it noninferior to placebo for major adverse cardiac events, even in men with elevated cardiovascular risk.
- Higher, non-physiologic testosterone doses appear more likely to reduce HDL than doses that restore levels to a normal physiological range.
- For those wondering how to lower cholesterol on TRT, evidence-based diet, exercise, and weight management strategies apply alongside routine lab monitoring.
- Cardiovascular risk monitoring, including lipid panels, blood pressure, and hematocrit, should be a standard part of any testosterone therapy program.
- Any significant lipid changes, chest discomfort, or unusual symptoms during TRT should be reported promptly to a healthcare provider.
Understanding your personal cholesterol and testosterone picture starts with data, not guesswork – explore hormone optimization through Ways2Well and consider comprehensive bloodwork to establish an accurate baseline before making any changes to your regimen. For related reading, see our articles on testosterone and metabolism and testosterone and blood pressure.
References
- Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. “Intramuscular Testosterone Esters and Plasma Lipids in Hypogonadal Men: A Meta-Analysis.” American Journal of Medicine, 2001;111(4):261-269. DOI: https://doi.org/10.1016/S0002-9343(01)00833-600833-6)
- Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. “Effects of Testosterone on Body Composition, Bone Metabolism and Serum Lipid Profile in Middle-Aged Men: A Meta-Analysis.” Clinical Endocrinology, 2005;63(3):280-293. DOI: https://doi.org/10.1111/j.1365-2265.2005.02339.x
- Zhang KS, Zhao MJ, An Q, Jia YF, Fu LL, Xu JF, Gu YQ. “Effects of Testosterone Supplementation Therapy on Lipid Metabolism in Hypogonadal Men with T2DM: A Meta-Analysis of Randomized Controlled Trials.” Andrology, 2018;6(1):37-46. DOI: https://doi.org/10.1111/andr.12425
- Mlynarz N, Miedziaszczyk M, Wieckowska B, Szalek E, Lacka K. “Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review.” International Journal of Molecular Sciences, 2024;25(22):12221. DOI: https://doi.org/10.3390/ijms252212221
- Lincoff AM, Bhasin S, Flevaris P, et al. (TRAVERSE Study Investigators). “Cardiovascular Safety of Testosterone-Replacement Therapy.” New England Journal of Medicine, 2023;389(2):107-117. DOI: https://doi.org/10.1056/NEJMoa2215025
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member